ClinicalTrials.gg
CompletedNCT07222878Updated Apr 3, 2026

Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042

A Phase 1 interventional study of NPT 2042 (Reference formula/Formulation 1) and NPT 2042 (Test formula/Formulation 2) in Epilepsy, Alzheimer Disease and Epilepsy Intractable, sponsored by NeuroPro Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-03.

Primary conditionDrug Resistant EpilepsyRegistry: EpilepsyReclassifiedWhy we changed it
Registry
Epilepsy — the first condition term the registry derived for this study.
ClinicalTrials.gg
Drug Resistant Epilepsy
Why
  1. The study's listed conditions name Drug Resistant Epilepsy, a narrower term within Epilepsy.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by NeuroPro Therapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
19 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies in Drug Resistant Epilepsy with a site in United States — 29 open to participants now, 34 under way, 2 of them phase 3. Drug Resistant Epilepsy · United States.

Enrollment
59th of 67
8 · median 27
Started
2025
with 7 others
Phase 1
9 of 78
3 open now
Registered
68th of 78
by date
Lead sponsor
2 of 78
NeuroPro Therapeutics, Inc.

Among the 78 studies in Drug Resistant Epilepsy with a site in United States, this one is the 59th largest by enrollment of the 67 interventional ones that give a count, is one of 8 that started in 2025, is one of 9 in phase 1, and was the 68th registered.

Drug Resistant Epilepsy

257 studies on the registry are indexed under Drug Resistant Epilepsy; 108 are open to participants now.

Browse Drug Resistant Epilepsy studies →

Open to participants now

29 of the 78 studies in Drug Resistant Epilepsy with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Drug Resistant Epilepsy studies recruiting now, 26 (39%) set no upper age limit and 39 (59%) stop at 75 or younger; 25 take children under 18; 6 take healthy volunteers.

This study: 19 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Drug Resistant Epilepsy with a site in United States, or all of them as a file.
02

Study summary

A Single-center, Open-label, Single-dose, Three-period, Fixed Sequence Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules

03

Conditions studied

  • Epilepsy
  • Alzheimer Disease
  • Epilepsy Intractable

Keywords

  • CNS Disorder
  • Seizure Disorder
04

In context

Drug Resistant Epilepsy Reclassified

257 studies on the registry are indexed under Drug Resistant Epilepsy; 108 are open to participants now.

This study's enrollment of 8 is below the median of 30 across 202 interventional studies indexed under Drug Resistant Epilepsy.

Browse Drug Resistant Epilepsy studies →

Lead sponsor

NeuroPro Therapeutics, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.

Compared within Drug Resistant Epilepsy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Epilepsy. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females between 19 and 65 years of age, inclusive.
  • (BMI) of 18 to 35 kg/m2, inclusive, using the following formula: weight (kg)/[height (m)]
  • A minimum body weight of 50 kg for males and 45 kg for females.
  • All females must have a negative serum pregnancy test at Screening and a negative serum pregnancy test upon admission to the clinical research center.
  • Females must be of non-.
  • Male participants with female partners of must agree to protocol specifications.

Exclusion criteria

Exclusion Criteria:

  • acute illness within 2 weeks prior to Day -1.
  • Presence of active or recurring clinically significant cardiovascular, pulmonary, renal, endocrine, hepatic, neurologic, psychiatric, immunologic, hematologic, gastrointestinal, or metabolic disease requiring medical treatment.
  • Presence of an active or a malignancy of any type within the past 5 years, other than squamous cell or basal cell carcinoma of the skin.
  • Clinically significant acute or chronic infection or known inflammatory condition.
  • Personal or family history of long syndrome.
  • History or evidence of adverse symptoms associated with phlebotomy or blood donation
  • History of clinically significant orthostatic hypotension or any vasovagal syncope.
  • Plans for surgery or other medical procedures during the study.
  • Clinically significant past or current medical or surgical history that could interfere with treatment.
  • Participation in an drug or device study within 30 days or five half-lives, whichever is longer [90 days for biologics], prior to dosing.
  • Presence of clinically significant illness or abnormality on physical examination.
  • Presence of clinically significant abnormality at Screening, including any QT interval corrected for heart rate (QTc) using Fridericia formula (QTcF) ≥470 msec.
  • Ongoing liver disease or unexplained liver function test (LFT) elevations, defined as (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), or alkaline phosphatase (ALP) greater than the (ULN).
  • Any other clinically significant laboratory results, as judged by the investigator.
  • History or presence of clinically significant (e.g. systemic or cutaneous) as judged by the investigator to NPT 2042.
  • History of substance abuse or current use of any drugs of abuse.
  • Blood donation of >500 mL or more within 56 days prior to Day -1.
  • Any other reason that, in the opinion of the investigator, would render the participant unsuitable for study enrollment.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    NPT 2042 80mg (Reference formulation) in Fasted State

    NPT 2042 80mgSingle-dose, reference formulation, given in fasted state.

    Drug: NPT 2042 (Reference formula/Formulation 1)

  • Experimental
    NPT 2042 80mg (Test formulation) in Fasted State

    NPT 2042 80mgSingle-dose, test formulation, given in fasted state.

    Drug: NPT 2042 (Test formula/Formulation 2)

  • Experimental
    NPT 2042 80mg (Test Formulation) in Fasted State with co-administered agent

    NPT 2042 80mgSingle-dose, test formulation, given in fasted state with co-administered agent.

    Drug: NPT 2042 (Test formula/Formulation 2)

Interventions

  • DrugNPT 2042 (Reference formula/Formulation 1)

    Drug page: NPT 2042

    In Period 1 Day 1, participants will receive Formulation 1 in a fasted state (Treatment A).

  • DrugNPT 2042 (Test formula/Formulation 2)

    Drug page: NPT 2042

    Following a 3-day wash out, in Period 2 Day 1, participants will receive Formulation 2 in a fasted state (Treatment B).

  • DrugNPT 2042 (Test formula/Formulation 2)

    Drug page: NPT 2042

    Following a 4-day wash out, in Period 3 Day 1, participants will receive Formulation 2 in a fasted state with co-administered agent (Treatment C).

07

What researchers measure

Primary outcomes

  1. To estimate the single dose pharmacokinetic parameters for each NPT 2042 formulation in healthy participants following each treatment.

    Plasma NPT 2042 PK endpoints including the Cmax (NPT 2042 only).

    Time frame: Baseline (Day -1) as compared to Tx. period 1 (Day 1), Tx. Period 2 (Day 4), and Tx. Period 3 (Day 7)

  2. To estimate the single dose pharmacokinetic parameters for each NPT 2042 formulation in healthy participants following each treatment.

    Plasma NPT 2042 PK endpoints including the Tmax (NPT 2042 only).

    Time frame: Baseline (Day -1) as compared to Tx. period 1 (Day 1), Tx. Period 2 (Day 4), and Tx. Period 3 (Day 7)

  3. To estimate the single dose pharmacokinetic parameters for each NPT 2042 formulation in healthy participants following each treatment.

    Plasma NPT 2042 PK endpoints including the t½ (NPT 2042 only).

    Time frame: Baseline (Day -1) as compared to Tx. period 1 (Day 1), Tx. Period 2 (Day 4), and Tx. Period 3 (Day 7)

  4. To estimate the single dose pharmacokinetic parameters for each NPT 2042 formulation in healthy participants following each treatment.

    Plasma NPT 2042 PK endpoints including the AUClast (NPT 2042 only).

    Time frame: Baseline (Day -1) as compared to Tx. period 1 (Day 1), Tx. Period 2 (Day 4), and Tx. Period 3 (Day 7)

  5. To estimate the single dose pharmacokinetic parameters for each NPT 2042 formulation in healthy participants following each treatment.

    Plasma NPT 2042 PK endpoints including the AUCinf (NPT 2042 only).

    Time frame: Baseline (Day -1) as compared to Tx. period 1 (Day 1), Tx. Period 2 (Day 4), and Tx. Period 3 (Day 7)

  6. To estimate the single dose pharmacokinetic parameters for each NPT 2042 formulation in healthy participants following each treatment.

    Plasma NPT 2042 PK endpoints including the CL/F (NPT 2042 only).

    Time frame: Baseline (Day -1) as compared to Tx. period 1 (Day 1), Tx. Period 2 (Day 4), and Tx. Period 3 (Day 7)

  7. To calculate the Frel and 90% confidence intervals for Formulation 1 (Reference) vs Formulation 2 (Test) both administered in a fasted state.

    The Frel calculations will be based on Cmax and AUCinf values for NPT 2042.

    Time frame: Baseline (Day -1) as compared to Tx. period 1 (Day 1) and Tx. Period 2 (Day 4)

08

Study locations

1 site
  • Celerion
    Lincoln, Nebraska 68502, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2025 to primary completion in Nov 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2025
First posted
Oct 30, 2025
StartActual
Sep 29, 2025
Primary completionActual
Nov 4, 2025
CompletionActual
Nov 4, 2025
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07222878
Lead sponsor
NeuroPro Therapeutics, Inc.
Responsible party
Sponsor
First posted
Oct 30, 2025
Start date
Sep 29, 2025
Primary completion
Nov 4, 2025
Completion
Nov 4, 2025
Last update
Apr 3, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NPT 2042

Start the discussion